S&P 500   3,624.44 (-0.30%)
DOW   29,871.40 (-0.58%)
QQQ   295.34 (+0.30%)
AAPL   116.13 (+0.83%)
MSFT   213.46 (-0.19%)
FB   274.18 (-0.99%)
GOOGL   1,759.90 (-0.23%)
AMZN   3,172.26 (+1.74%)
TSLA   564.26 (+1.60%)
NVDA   528.41 (+1.95%)
BABA   275.82 (-1.48%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   63.01 (-1.47%)
AMD   86.27 (+1.41%)
T   29.02 (-0.72%)
NIO   53.20 (-0.58%)
F   9.12 (-3.49%)
ACB   8.62 (-6.61%)
NFLX   481.40 (-0.31%)
GILD   59.67 (-0.96%)
BA   217.76 (-0.33%)
DIS   148.45 (-2.01%)
S&P 500   3,624.44 (-0.30%)
DOW   29,871.40 (-0.58%)
QQQ   295.34 (+0.30%)
AAPL   116.13 (+0.83%)
MSFT   213.46 (-0.19%)
FB   274.18 (-0.99%)
GOOGL   1,759.90 (-0.23%)
AMZN   3,172.26 (+1.74%)
TSLA   564.26 (+1.60%)
NVDA   528.41 (+1.95%)
BABA   275.82 (-1.48%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   63.01 (-1.47%)
AMD   86.27 (+1.41%)
T   29.02 (-0.72%)
NIO   53.20 (-0.58%)
F   9.12 (-3.49%)
ACB   8.62 (-6.61%)
NFLX   481.40 (-0.31%)
GILD   59.67 (-0.96%)
BA   217.76 (-0.33%)
DIS   148.45 (-2.01%)
S&P 500   3,624.44 (-0.30%)
DOW   29,871.40 (-0.58%)
QQQ   295.34 (+0.30%)
AAPL   116.13 (+0.83%)
MSFT   213.46 (-0.19%)
FB   274.18 (-0.99%)
GOOGL   1,759.90 (-0.23%)
AMZN   3,172.26 (+1.74%)
TSLA   564.26 (+1.60%)
NVDA   528.41 (+1.95%)
BABA   275.82 (-1.48%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   63.01 (-1.47%)
AMD   86.27 (+1.41%)
T   29.02 (-0.72%)
NIO   53.20 (-0.58%)
F   9.12 (-3.49%)
ACB   8.62 (-6.61%)
NFLX   481.40 (-0.31%)
GILD   59.67 (-0.96%)
BA   217.76 (-0.33%)
DIS   148.45 (-2.01%)
S&P 500   3,624.44 (-0.30%)
DOW   29,871.40 (-0.58%)
QQQ   295.34 (+0.30%)
AAPL   116.13 (+0.83%)
MSFT   213.46 (-0.19%)
FB   274.18 (-0.99%)
GOOGL   1,759.90 (-0.23%)
AMZN   3,172.26 (+1.74%)
TSLA   564.26 (+1.60%)
NVDA   528.41 (+1.95%)
BABA   275.82 (-1.48%)
CGC   26.96 (-0.04%)
GE   10.49 (+0.38%)
MU   63.01 (-1.47%)
AMD   86.27 (+1.41%)
T   29.02 (-0.72%)
NIO   53.20 (-0.58%)
F   9.12 (-3.49%)
ACB   8.62 (-6.61%)
NFLX   481.40 (-0.31%)
GILD   59.67 (-0.96%)
BA   217.76 (-0.33%)
DIS   148.45 (-2.01%)
Log in
NASDAQ:APLS

Apellis Pharmaceuticals Stock Forecast, Price & News

$47.28
-0.32 (-0.67 %)
(As of 11/25/2020 11:34 AM ET)
Add
Compare
Today's Range
$46.93
Now: $47.28▼
$47.78
50-Day Range
$31.55
MA: $36.50▼
$47.85
52-Week Range
$16.85
Now: $47.28▼
$49.42
Volume5,141 shs
Average Volume975,004 shs
Market Capitalization$3.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.12
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Waltham, Massachusetts.
Read More
Apellis Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLS
Previous Symbol
CUSIPN/A
CIK1492422
Webwww.apellis.com
Phone617-977-5700
Employees297

Debt

Debt-to-Equity Ratio3.34
Current Ratio9.86
Quick Ratio9.86

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.40 per share
Price / Book33.77

Profitability

EPS (Most Recent Fiscal Year)($4.64)
Net Income$-304,710,000.00
Net MarginsN/A
Return on Equity-336.93%
Return on Assets-78.28%

Miscellaneous

Outstanding Shares75,737,000
Market Cap$3.58 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableNot Optionable
$47.28
-0.32 (-0.67 %)
(As of 11/25/2020 11:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

How has Apellis Pharmaceuticals' stock been impacted by COVID-19?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, APLS stock has increased by 73.6% and is now trading at $47.28.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Apellis Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Apellis Pharmaceuticals.

What stocks does MarketBeat like better than Apellis Pharmaceuticals?

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Apellis Pharmaceuticals.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its earnings results on Saturday, November, 7th. The company reported ($1.79) EPS for the quarter, missing the consensus estimate of ($1.58) by $0.21. The firm had revenue of $0.65 million for the quarter.
View Apellis Pharmaceuticals' earnings history.

What price target have analysts set for APLS?

18 brokerages have issued 1-year price targets for Apellis Pharmaceuticals' shares. Their forecasts range from $29.00 to $86.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $52.65 in the next year. This suggests a possible upside of 11.4% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals.

Who are some of Apellis Pharmaceuticals' key competitors?

Some companies that are related to Apellis Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Grifols (GRFS), MyoKardia (MYOK), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Ascendis Pharma A/S (ASND), Galapagos (GLPG), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS) and Bausch Health Companies (BHC).
View all competitors.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:
  • Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 48, Pay $987.91k)
  • Dr. Pascal Deschatelets, Co-Founder & Chief Scientific Officer (Age 50, Pay $712.58k)
  • Mr. Alec Machiels J.D., MBA, Co-Founder & Independent Director (Age 47, Pay $61.75k)
  • Mr. Timothy E. Sullivan, Chief Financial Officer (Age 49, Pay $610.65k)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 46)
  • Ms. Nur Nicholson, Chief Technical Operations Officer
  • Mr. David O. Watson, Gen. Counsel (Age 47)
  • Ms. Karen Lewis, Chief People Officer
  • Dr. Lukas Scheibler M.D., Ph.D., Chief Innovation Officer (Age 49)
  • Mr. Adam J. Townsend, Chief Commercial Officer (Age 43)

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.90%), State Street Corp (3.78%), Jennison Associates LLC (3.75%), Victory Capital Management Inc. (2.83%), Candriam Luxembourg S.C.A. (1.52%) and Fiduciary Trust Co. (0.75%). Company insiders that own Apellis Pharmaceuticals stock include Alec Machiels, Cedric Francois, Federico Grossi, Morningside Venture Investment, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals.

Which institutional investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Candriam Luxembourg S.C.A., Fiduciary Trust Co., Morgan Stanley, AQR Capital Management LLC, Great West Life Assurance Co. Can, and Cubist Systematic Strategies LLC. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include Alec Machiels, Cedric Francois, Federico Grossi, and Victoria L Brown.
View insider buying and selling activity for Apellis Pharmaceuticals.

Which institutional investors are buying Apellis Pharmaceuticals stock?

APLS stock was purchased by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Victory Capital Management Inc., DekaBank Deutsche Girozentrale, Rhenman & Partners Asset Management AB, State of New Jersey Common Pension Fund D, AXA S.A., and Assenagon Asset Management S.A.. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan.
View insider buying and selling activity for Apellis Pharmaceuticals.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $47.28.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $3.58 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Apellis Pharmaceuticals employs 297 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.